<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Iran J Child Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Iran J Child Neurol</journal-id>
<journal-id journal-id-type="publisher-id">IJCN</journal-id>
<journal-title-group>
<journal-title>Iranian Journal of Child Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1735-4668</issn>
<issn pub-type="epub">2008-0700</issn>
<publisher>
<publisher-name>Shahid Beheshti University of Medical Sciences</publisher-name>
<publisher-loc>Tehran, Iran</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30026765</article-id>
<article-id pub-id-type="pmc">6045935</article-id>
<article-id pub-id-type="publisher-id">ijcn-12-003</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurological Manifestations of Primary Immunodeficiencies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>CHAVOSHZADEH</surname>
<given-names>Zahra</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>HASHEMITARI</surname>
<given-names>Amir</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>DAROUGAR</surname>
<given-names>Sepideh</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>Department of Immunology and Allergy, Mofid’s Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff>
<aff id="aff2">
<label>2</label>East London NHS Foundation Trust,London,United Kingdom</aff>
<aff id="aff3">
<label>3</label>Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff>
<author-notes>
<corresp id="cor">Corresponding author: Darougar S. MD, Email: sepidehdarougar@yahoo.com, Address: Dr.Masih Daneshvari Hospital, Daar-Abad, Niavaran,Tehran, Iran. Phone Number:+989122881975</corresp>
</author-notes>
<pub-date pub-type="ppub">
<season>Summer</season>
<year>2018</year>
</pub-date>
<volume>12</volume>
<issue>3</issue>
<fpage>7</fpage>
<lpage>23</lpage>
<history>
<date date-type="received">
<day>29</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>6</month>
<year>2018</year>
</date>
</history>
<permissions>
<license license-type="open-access">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective:</title>
<p>Primary immunodeficiencies (PID) are a heterogeneous group of disorders with a variable clinical spectrum of manifestations. The central nervous system may be involved in PID with symptoms which may present initially or develop at later stages. The purpose of this study was to review the neurological manifestations of different PID syndromes.</p>
</sec>
<sec>
<title>Materials &amp; Methods:</title>
<p>We focused on 104 selected studies on PID with certain neurological abnormalities which may accompany these disorders or may later signify a PID in their course.</p>
</sec>
<sec>
<title>Results:</title>
<p>Diverse neurological deficits accompanying certain PIDs may be mild or they may greatly influence the course of the disease with major impacts on the quality of life of these patients.</p>
</sec>
<sec>
<title>Conclusion:</title>
<p>Early recognition and treatment is important to prevent or reduce future irreversible neurological sequelae. Therefore physicians should be aware of the neurological features accompanying PID.</p>
</sec>
</abstract>
<kwd-group>
<title>Key Words</title>
<kwd>Neurological</kwd>
<kwd>Primary immunodeficiencies</kwd>
<kwd>Neurologic signs and symptoms</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Primary immunodeficiencies (PID) are a heterogeneous group of 354 distinct disorders with 344 different gene defects (<xref ref-type="bibr" rid="B1">1</xref>) with a variable clinical spectrum of manifestations. A diagnosis of PID will often be considered with a predisposition to frequent, severe or unusual infections, autoimmune disorders and malignancies or allergic disorders (<xref ref-type="bibr" rid="B2">2</xref>). </p>
<p>PIDs have been classified practically according to the affected immune function to the following groups: immunodeficiencies affecting cellular and humoral immunity, combined immunodeficiencies with associated or syndromic features, antibody deficiencies, diseases of immune dysregulation, congenital defects of phagocytes, defects in intrinsic and innate immunity, autoinflammatory disorders, complement deficiencies and phenocopies of PIDs (<xref ref-type="bibr" rid="B3">3</xref>). The central nervous system may be involved in PIDs with symptoms which may present initially or develop at later stages. The neurological symptoms may vary from mild cognitive defects to severe disabilities (<xref ref-type="bibr" rid="B4">4</xref>). Physical examination may give the clinician valuable clues to the cause of PIDs that underlie the neurological signs. Certain neurological abnormalities may later signify a PID. Therefore physicians should be aware of the neurological features accompanying immunodeficiencies. Neuromascular abnormality presenting with ataxia may be the first indicator of ataxia-telengiectasia. Flaccid paralysis after live poliovirus immunization may suggest combined immunodeficiency or antibody defects. Pernicious anaemia may later result in neurological deficits in untreated CVID patients. Cognitive impairment, nystagmus and cerebellar, spinal and peripheral neuropathies are neurologic features seen in Chediac-Higashi Syndrome. Patients with Griscelli syndrome may present with seizures, ataxia and occulomotor and reflex abnormalities. DiGeorge anomaly may present with subtle developmental delays later manifesting as problem with school performances (<xref ref-type="bibr" rid="B5">5</xref>). Early recognition and treatment may prevent or reduce future irreversible neurological sequelae (<xref ref-type="bibr" rid="B4">4</xref>). </p>
<p>Neurological manifestations will be discussed in detail according to the specific classification of primary immunodeficiencies to assist the treating physicians’ timely diagnosis and prompt treatment in order to avoid irreversible neurologic sequelae. The categorization of the inborn errors of immunity is based on the International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity (<xref ref-type="bibr" rid="B1">1</xref>).</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials &amp; Methods</title>
<p>The last version of IUIS Primary Immunodeficiencies Committee Report (<xref ref-type="bibr" rid="B1">1</xref>) on Inborn Errors of Immunity was reviewed first to select certain PIDs with neurological manifestations. Then a review of literature was started according to specific PID associated with neurological manifestations with a focus on 104 selected studies.</p>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Immunodeficiencies affecting cellular and humoral immunity</p>
<p> Severe combined immunodeficiencies defined by CD3 T cell lymphopenia</p>
<p>
<bold>Adenosine Deaminase deficiency (ADA)</bold>
</p>
<p>ADA is a ubiquitous enzyme in purine salvage pathway which is also expressed in both the peripheral and central nervous systems (<xref ref-type="bibr" rid="B6">6</xref>). ADA deficiency is caused by mutations in the ADA gene and is known as one of the most prevalent forms of severe combined immunodeficiencies (<xref ref-type="bibr" rid="B6">6</xref>). The most common manifestations include recurrent and opportunistic fungal, viral and bacterial infections, lymphopenia and failure to thrive (<xref ref-type="bibr" rid="B7">7</xref>). The main neurologic manifestations of these diseases result from accumulation of adenosine metabolites in basal ganglia and thalamus which are rich in adenosine receptors. These neurologic abnormalities include motor delay, hypotonia, mental retardation, learning disability, hyperactivity, attention deficit, behavioural abnormalities, reduced verbal expression, seizure and sensorineural deafness (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B8">8</xref>). One infant has been reported with nystagmus and difficulty in focusing gaze was found to have brain atrophy on MRI (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>
<bold>DNA Ligase IV deficiency</bold>
</p>
<p>This autosomal recessive form of SCID is caused by an impairment of the DNA damage repair process with a pronounced radiosensitivity (<xref ref-type="bibr" rid="B10">10</xref>). DNA double-strand break repair via non-homologous end-joining (NHEJ) is involved in recombination of immunoglobulin and T-cell receptor genes. Mutations in NHEJ components may lead to microcephaly and immunodeficiency (<xref ref-type="bibr" rid="B11">11</xref>).The neurological manifestations of this disease include microcephaly and developmental delay (<xref ref-type="bibr" rid="B12">12</xref>). </p>
<p>
<bold>Cernunnos deficiency</bold>
</p>
<p>This is another rare autosomal recessive form of SCID with severe T and B lymphopenia and dysgammaglobulinemia in addition to radiosensitivity caused by mutations in the CERNUNNOS or XRCC4-like factor (XLF). Microcephaly and developmental delay are the prominent neurological features (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B8">8</xref>). </p>
<p>
<bold>CID with associated or syndromic features</bold>
</p>
<p>
<bold>Ataxia-Telengiectasia</bold>
</p>
<p>This autosomal recessive complex disorder with substantial severity in affected individuals (<xref ref-type="bibr" rid="B13">13</xref>) is characterized by ataxia, ocular and cutaneous telengiectasia, radiosensitivity, immunodeficiency, increased predisposition to malignancies (<xref ref-type="bibr" rid="B14">14</xref>) and elevated serum alpha fetoprotein level. Sinopulmonary infections (<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>) are common in these patients with development of chronic lung disease in 25% (<xref ref-type="bibr" rid="B18">18</xref>). The most common immunologic abnormalities are low serum levels of one or more classes of immunoglobulin, failure to make antibodies in response to vaccines and lymphopenia (<xref ref-type="bibr" rid="B19">19</xref>). The ataxia telengiectasia mutated (ATM) gene is involved in the response to DNA damage in the nervous system which leads to impaired apoptosis and elimination of the damaged neurons and neurodegeneration (<xref ref-type="bibr" rid="B4">4</xref>). Progressive neurodegeneration which mainly occurs with a widespread loss of Purkinje cells in cerebellum is the hallmark of ataxia-telengiectasia, manifesting as head and trunk swaying and gait abnormalities (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>). It is followed by basal ganglia dysfunction later in the course of the disease characterised by hypotonia, tremor and choreoathetosis. These patients are usually confined to a wheelchair by the age of 10-12 years of age. In physical examination, further evaluation reveals diminished or absent tendon reflexes, positive Babinski sign, loss of vibration sense, abnormal ocular motility, reduction in sensory conduction velocity and axonal degeneration of peripheral nerves (<xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>There are also Ataxia Telengiectasia-Like Disorders (ATLD) which are clinically similar to ataxia telengiectasia although without telangiectasia and a slower progression of neurologic manifestations. These patients remain ambulatory until their third decades of lives (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B20">20</xref>).</p>
<p>
<bold>Nijmegan Breakage Syndrome</bold>
</p>
<p>This is a rare autosomal recessive, multisystemic disease of chromosomal instability presenting at birth with microcephaly but no additional neurologic manifestation (<xref ref-type="bibr" rid="B21">21</xref>). The mutated gene (NBS) has a critical role in responding to DNA damage. The defect leads to neuronal loss and microcephaly. “Other manifestations include combined cellular and humoral immunodeficiency with recurrent sinopulmonary infections, a strong predisposition to develop malignancies and radiosensitivity” (<xref ref-type="bibr" rid="B21">21</xref>). Due to the radiation hypersensitivity in these patients, they are at increased risk of developing brain malignancies such as medulloblastoma (<xref ref-type="bibr" rid="B22">22</xref>). These patients may exhibit progressive mental retardation which becomes more evident after age of 14 years (<xref ref-type="bibr" rid="B23">23</xref>). As well as brain developmental abnormalities including partial collosal agenesis, hydrocephaly, colpocephaly, neuronal migration abnormalities. The volume of the frontal lobe may be reduced and the gyral pattern may become simplified (<xref ref-type="bibr" rid="B24">24</xref>). </p>
<p>
<bold>Immunodeficiency, Centromeric Region Instability and Facial Anomalies Syndrome</bold>
</p>
<p>This genetic disease is due to a mutation in DNA methylteransferase gene (<xref ref-type="bibr" rid="B25">25</xref>) which causes DNA hypomethylation. It is not identified how these hypomethylated areas of the genome result in the features of this syndrome but it appears that the expression pattern of the genes essential for a functional immune system, craniofacial development and neurogenesis are altered in the deficient cells (<xref ref-type="bibr" rid="B26">26</xref>). ICF patients have severe respiratory infections and recurrent gastrointestinal infections due to immune abnormalities which include hypogammaglobulinemia despite normal B cell counts and a mild reduction in immune response. Reduced T cell counts have been detected in approximately half of the cases (<xref ref-type="bibr" rid="B99">99</xref>). Affected patients exhibit mental retardation, hypotonia and ataxia in addition to above immune abnormalities (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B27">27</xref>).</p>
<p>
<bold>Riddle Syndrome</bold>
</p>
<p>This syndrome is characterized by a defect in DNA damage response causing immunodeficiency and increased radiosensitivity accompanied by neurologic symptoms and growth delay due to an increased apoptosis and reduced proliferative capacity during brain development presenting as mild motor control and learning difficulties (<xref ref-type="bibr" rid="B28">28</xref>). </p>
<p>
<bold>DiGeorge Syndrome</bold>
</p>
<p>In addition to the characterizing triad of cardiac defects, hypocalcemia and cellular immune deficiency, there may be neurological manifestations which present with developmental delay in motor, language and speech areas, neuropsychiatric problems and epilepsy (<xref ref-type="bibr" rid="B4">4</xref>). Most patients show a hemizygous chromosome 22q11.2 deletion, and most of them with DiGeorge syndrome show mild to moderate T cell lymphopenia. The most common neurologic manifestations include cognitive, neurologic and psychiatric abnormalities (<xref ref-type="bibr" rid="B8">8</xref>). Nearly 50% percent of school-age patients have problems with persistent language difficulties while their full-scale IQ scores are within normal to moderately retarded range with math scales lower than reading and spelling (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>). Behavioural abnormalities include anxiety disorders, schizophrenia, ADHD, mood disorders and flat effect in childhood (<xref ref-type="bibr" rid="B31">31</xref>) and schizophrenia and bipolar disorders later during adulthood. Neural tube defects, polymicrogyria, volume reduction in the corpus callosum, amygdalae and temporoparietal regions (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B32">32</xref>) and myelomeningocele (<xref ref-type="bibr" rid="B33">33</xref>) are structural malformations which have been described in these patients.</p>
<p>
<bold>Hyper-immunoglobulin E syndrome</bold>
</p>
<p>These syndromes are characterized by recurrent skin and pulmonary infections in the presence of elevated IgE concentrations and usually eosinophilia. The hyper-IgE syndromes have four distinct genetic causes including mutations in signal transducer and activator of transcription 3 (STAT3), dedicator of cytokinesis 8 (DOCK8), tyrosine kinase2 (TYK2) and phosphoglucomutase 3 (PGM3) (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B34">34</xref>). Vascular abnormalities, impaired myelination or autoimmunity are the main suggested causes for neurologic manifestations in these patients (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Intracranial manifestations including Chiari I malformations and focal hyperintensities on brain MRI are the two findings in AD-HIED which are typically asymptomatic (<xref ref-type="bibr" rid="B37">37</xref>). Other CNS reported abnormalities include vasculitis resulting a right parietal infarction and thrombosis of the left posterior inferior cerebellar artery (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). In DOCK8 deficiency neurologic manifestations include vasculitis, ischemic infarction, hemiplegia, facial paralysis, subarachnoid hemorrhages and progressive multifocal leukoencephalopathy (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B40">40</xref>). Patients with PGM3 mutations are reported to carry a high risk of early onset neurological impairment including developmental delay, ataxia, dysarthria, psychomotor retardation, hypotonia, sensorineural hearing loss, seizures and myoclonus (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B41">41</xref>).</p>
<p>
<bold>Schimke Immuno-osseous Dysplasia</bold>
</p>
<p>This autosomal recessive disorder is caused by mutation in the SMARCAL1 gene which encodes a chromatin remodeling protein. Defective cellular immunity causes recurrent bacterial, fungal and viral infections which in association with short stature and progressive renal insufficiency characterizes the disorder (<xref ref-type="bibr" rid="B4">4</xref>). Neurological manifestations include early-onset cerebral ischemic attacks, Migraine-type headaches (<xref ref-type="bibr" rid="B42">42</xref>), optic neuropathy, seizures, mental retardation and behavioural changes (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B43">43</xref>). Progressive aterosclerosis and intrinsic neurovascular defects are considered as the underlying pathologic involvement causing the above manifestations (<xref ref-type="bibr" rid="B44">44</xref>).</p>
<p>
<bold>Hoyeraal-Hreidarsson syndrome</bold>
</p>
<p>This is an X-linked recessive disorder of telomere dysfunction which represents a severe form of dyskeratosis congenita characterized by a classic triad of reticular skin pigmentation, dysplastic nails and oral leukoplakia (<xref ref-type="bibr" rid="B45">45</xref>). Pancytopenia and severe combined immunodeficiency (characterized by a decreased B cells count and Natural Killer cells and low immunoglobulin levels that can affect all immunoglobulin subtypes) may eventually develop (<xref ref-type="bibr" rid="B46">46</xref>). Dyskerin, a highly conserved protein is the product of DKC1 gene, involved in ribosome biogenesis and acts as a component of telomerase complex (<xref ref-type="bibr" rid="B8">8</xref>). Since proper telomerase activity is essential for early development of neural progenitor cells and neurons, its defective function may lead to increased susceptibility to DNA damage and apoptosis and the resultant neurologic deficits. These neurological abnormalities include microcephaly, psychomotor retardation, spasticity, cerebellar hypoplasia, ataxia (<xref ref-type="bibr" rid="B8">8</xref>), seizures and axial hypotonia (<xref ref-type="bibr" rid="B47">47</xref>).</p>
<p>
<bold>Purine Nucleoside Phosphorylase Deficiency</bold>
</p>
<p>This rare autosomal recessive metabolic disorder, similar to ADA deficiency, results from impaired purine salvage pathway which causes combined immunodeficiency in association with prominent neurological abnormalities (<xref ref-type="bibr" rid="B48">48</xref>). “Mutations in PNP results in impaired function of enzyme leading to accumulation of purine metabolites such as deoxy-guanosine triphosphate (dGTP) which preferentially is accumulated in mitochondria and will affect adversely mitochondrial DNA repair and therefore may induce subsequent neuronal cell apoptosis” (<xref ref-type="bibr" rid="B8">8</xref>). Patients present with T-lymphocytopenia (<xref ref-type="bibr" rid="B49">49</xref>). Infectious complications include recurrent upper and lower respiratory tract infections and otitis media (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>). Neurological findings found in more than half of the patients often precede infections and autoimmunity (<xref ref-type="bibr" rid="B4">4</xref>) and include motor system dysfunction, cerebral palsy, hyper/ hypotonia, spastic paresis, tremor, ataxia, mental retardation, developmental delay, behavioural problems, cerebrovascular accidents and sensorineural deafness (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B50">50</xref>). </p>
<p>
<bold>Hepatic Veno-Occlusive Disease with Immunodeficiency</bold>
</p>
<p>This is caused by homozygous mutation in the autosomal SP110 gene. The onset of clinical features usually occurs before the age of six months with hepatic sinusoidal obstruction. Serum Ig levels are low. T cell subsets and B-cell numbers are reduced. Neurological abnormalities include leukodystrophy and extensive cerebral necrosis on postmortem examination are found in one third of the patients (<xref ref-type="bibr" rid="B51">51</xref>).</p>
<p>
<bold>VICI Syndrome (Immunodeficiency with Cleft Lip/Palate, Cataract, Hypopigmentation and Absent Corpus Collasum)</bold>
</p>
<p>This rare autosomal recessive disorder is caused by mutation in the EPG5 gene which results in defective autophagy (<xref ref-type="bibr" rid="B52">52</xref>). Clinical findings include cataracts, cleft lip and palate, progressive cardiomyopathy, variable pigmentary defects and combined immunodeficiencies. Neurologic manifestations include microcephaly, seizures, nystagmus, callosal agenesis, hypotonia and severe psychomotor and growth retardation (<xref ref-type="bibr" rid="B53">53</xref>). Some patients show more structural CNS abnormalities (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>). </p>
<p>
<bold>Predominantly Antibody deficiency</bold>
</p>
<p>Common variable immunodeficiencies and agammaglobulinemia (x-linked or autosomal recessive) are the most frequent forms of presentations of antibody deficiency. Symptoms mainly consist of respiratory or gastrointestinal involvement. However, neurologic manifestations may also occur. </p>
<p>
<bold>Common Variable Immunodeficiency</bold>
</p>
<p>Neurologic manifestations are a complex of diverse and rare complications of CVID including brain or spinal cord infections (meningitis as the most common neurologic manifestation), autoimmune involvements (featuring as axonal sensorimotor polyneuropathy) (<xref ref-type="bibr" rid="B54">54</xref>), transverse myelitis (<xref ref-type="bibr" rid="B55">55</xref>), progressive neurodegeneration (<xref ref-type="bibr" rid="B56">56</xref>), cerebral vasculitis (causing recurrent occipital headaches), brain granulomatous lesions (<xref ref-type="bibr" rid="B57">57</xref>), free radical mediated neuronal damage due to vitamin E deficiency (including sensory loss, ataxia, retinitis pigmentosa) (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B59">59</xref>), subacute combined degeneration of the cord secondary to vitamin B12 deficiency, peroneal muscular atrophy, Guillain-Barre syndrome and myasthenia gravis (<xref ref-type="bibr" rid="B55">55</xref>).</p>
<p>
<bold>Agammaglobulinemia</bold>
</p>
<p>In patients with agammaglobulinemia symptoms mainly consist of recurrent respiratory or gastrointestinal infections. Serum immunoglobulins are severely decreased and usually undetectable (<xref ref-type="bibr" rid="B60">60</xref>). CNS complications may arise from persistent enteroviral infections which may lead to fatal encephalitis or dermatomyositis-meningoencephalitis syndrome (<xref ref-type="bibr" rid="B61">61</xref>). “Also, a progressive encephalopathy of unknown etiology has been described in patients with x-linked agammaglobulinemia with a uniform clinical course including cognitive and movement disorders” (<xref ref-type="bibr" rid="B62">62</xref>).</p>
<p>
<bold>Disorders of Immune Regulation</bold>
</p>
<p>
<bold>Chediac Higashi Syndrome</bold>
</p>
<p>Patients with this autosomal recessive lethal disorder present with recurrent respiratory and bacterial skin infections due to severe immunodeficiency, partial oculocutaneous albinism, bleeding tendency and progressive neurological features (<xref ref-type="bibr" rid="B63">63</xref>). This syndrome is caused by mutations in the lysosomal trafficking regulator gene (LYST) (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Neurologic abnormalities include weakness, areflexia, sensory deficits, peripheral polyneuropathy, progressive neurodegeneration, cognitive defects, dementia, ataxia, tremor, seizures, autonomic dysfunction and parkinsonian syndrome (<xref ref-type="bibr" rid="B64">64</xref>). Unfortunately the progression of neurological manifestations is not arrested by HSCT (<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>).</p>
<p>
<bold>Hermansky-Pudlak syndrome type 2</bold>
</p>
<p>Among Hermansky Pudlak syndromes, this type is characterized by an immunodeficiency due to neutropenia and T lymphocyte dysfunction which differentiates it from other types of this syndrome (<xref ref-type="bibr" rid="B66">66</xref>). These patients usually suffer from recurrent bacterial infections, particularly respiratory illnesses, hepatosplenomegaly, lung fibrosis, dysmorphia, oculocutaneous albinism, thrombocytopenia and neurological abnormalities (<xref ref-type="bibr" rid="B67">67</xref>). Neurological manifestations include developmental delay, generalized seizures, microcephaly, hearing impairment and intention tremor (<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B69">69</xref>).</p>
<p>
<bold>Familial Hemophagocytic Lymphohistiocytosis</bold>
</p>
<p>FHL comprises a group of autosomal recessive life-threatening disorders characterized by uncontrolled proliferation of activated lymphocytes and macrophages associated with massive secretion of cytokines infiltrating into organs including lymph nodes, bone marrow, liver, spleen and central nervous system (<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B71">71</xref>). CNS infiltration begins in the meninges, progressing to diffuse infiltration of the white matter followed by necrosis and focal demyelination (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B71">71</xref>). Therefore neurological manifestations vary depend on the areas involved including seizures, decreased level of consciousness, facial palsy, irritability, bulging fontanel, dysphagia, dysarthria, CSF abnormalities (leukocytosis), ataxia, nystagmus, visual disturbance, neck stiffness, cranial nerve palsies and brain death (<xref ref-type="bibr" rid="B72">72</xref>-<xref ref-type="bibr" rid="B74">74</xref>).</p>
<p>
<bold>Congenital defects of phagocytic number or function</bold></p>
<p>
<bold>Chronic Granulomatous Disease</bold>
</p>
<p>Chronic granulomatous disease is the most common inherited disorder of phagocytic cells. It results from an inability of phagocytes to produce bactericidal superoxide anions due to defects of the NADPH oxidase system and it leads to the defect in killing of a specific spectrum of bacteria and fungi resulting in concomitant hyper-inflammation and tissue granuloma formation (<xref ref-type="bibr" rid="B75">75</xref>). Neurological manifestations are reported due to brain abscesses which are rare events in CGD (<xref ref-type="bibr" rid="B76">76</xref>). Other complications include white matter disease, CNS granulomatous disease and leptomeningeal and focal brain infiltration by pigmented lipid-laden macrophages (<xref ref-type="bibr" rid="B75">75</xref>).</p>
<p>
<bold>Severe Congenital Neutropenia</bold>
</p>
<p>This term is used for a heterogeneous group of primary immunodeficiencies including sporadic autosomal recessive, autosomal dominant and x-linked types (<xref ref-type="bibr" rid="B39">39</xref>) of which the autosomal recessive type with a homozygous mutation in antiapoptotic protein, HAX1, accounts for one third of these patients and has been identified as the only subtype associated with neurologic abnormalities (<xref ref-type="bibr" rid="B40">40</xref>). Neurologic manifestations include developmental delay, cognitive defects, speech defects, attention deficit, hyperactivity, learning disabilities and epilepsy (<xref ref-type="bibr" rid="B77">77</xref>-<xref ref-type="bibr" rid="B79">79</xref>). </p>
<p>
<bold>Schwachman-Diamond Syndrome</bold>
</p>
<p>This is a multisystem disorder characterized by bone marrow failure, exocrine pancreatic insufficiency and metaphyseal chondrodysplasia. These features are attributed to mutation in SBDS gene (<xref ref-type="bibr" rid="B80">80</xref>). However the precise pathologic pathways with the potential ability to disrupt the protein’s function remain to be identified. Neurological findings include neuropsychological abnormalities. These patients not only suffer from behavioural problems but also experience developmental retardation, low intelligence, cognitive deficits, hypotonia and visual motor dysfunction (<xref ref-type="bibr" rid="B81">81</xref>). Brain structural anomalies including callosal agenesis, delayed myelination and decreased gray and white matter volumes have been detected (<xref ref-type="bibr" rid="B82">82</xref>).</p>
<p>
<bold>Leukocyte Adhesion Deficiency type 2</bold>
</p>
<p>LAD syndromes consist of rare autosomal recessive disorders among which only LAD type 2 presents with neurologic abnormalities. These patients are characterized by recurrent bacterial infections without pus formation in the first years of life and severe mental retardation later (<xref ref-type="bibr" rid="B83">83</xref>). Other neurologic manifestations include autistic features, microcephaly, muscular hypotonia and cerebral atrophy (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>). Strong delays in directional movement and severe retardation in speech development have been also reported (<xref ref-type="bibr" rid="B84">84</xref>). Impaired fucose metabolism has been suggested as the cause of neurologic manifestations (<xref ref-type="bibr" rid="B85">85</xref>).</p>
<p>
<bold>β-Actin deficiency</bold>
</p>
<p>This autosomal dominant immunodeficiency disorder caused by a non-lethal mutation, characterized by defects in neutrophil migration, mental retardation, short stature, thrombocytopenia and photosensitivity (<xref ref-type="bibr" rid="B86">86</xref>). The hallmark of the disorder is recurrent bacterial and fungal infections without pus formation. The neurologic manifestations of this defect are due to the contribution of β-actin in neuronal migration and development and particularly includes mental retardation. </p>
<p>
<bold>Autoinflammatory Disorders</bold>
</p>
<p>
<bold>Mevalonate Kinase Deficiency (MKD)</bold>
</p>
<p>This is a term used for a wide clinical spectrum of autosomal recessive disorders due to a congenital error in cholesterol biosynthesis, with hyperimmunoglobulinemia D syndrome as the benign variant of the disorder and Mevalonic aciduria as the more severe form of MKD (<xref ref-type="bibr" rid="B3">3</xref>). Mevalonate kinase is an important enzyme in the biosynthesis of cholesterol. Recurrent, non-infectious febrile episodes lasting 4 to 6 days, usually accompanied by cervical or abdominal lymphadenopathies, splenomegaly, vomiting, diarrhoea, arthralgia and erythematous/ urticarial rash are characteristic. Although the pathogenic mechanisms causing the neurological defects are not understood, the role of cholesterol in brain development and neuronal function cannot be ignored. The neurological manifestations in a subset of patients with hyperimmunoglobulinemia D syndrome include mental retardation, ataxia and epilepsy (<xref ref-type="bibr" rid="B87">87</xref>). In patients with mevalonic aciduria due to complete MVK deficiency, neurological manifestations may include dysmorphic craniofacial features, psychomotor retardation, developmental delay, hypotonia and progressive cerebellar ataxia (<xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B89">89</xref>). </p>
<p>
<bold>Neonatal Onset Multisystem Inflammatory Disorder</bold>
</p>
<p>The disease results from mutations in the CIAS-1 gene which encodes cryopyrin (<xref ref-type="bibr" rid="B90">90</xref>). Cryopyrin in association with other proteins form a protein complex called the inflammasome which activates IL-1β to its proinflammatory form. These mutations cause which aberrant activation of the inflammasome (<xref ref-type="bibr" rid="B91">91</xref>) are supposed to be responsible for the persistent upregulation of this inflammatory pathway (<xref ref-type="bibr" rid="B92">92</xref>). Therefore like other involved organs, the increased IL-1β activity (<xref ref-type="bibr" rid="B93">93</xref>) in the brain seems to cause the neurological symptoms which are the prominent manifestations of this disorder. These abnormalities include chronic aseptic meningitis which may cause increased intracranial pressure resulting in hydrocephalus, papilledema and optic nerve atrophy, spastic diplegia, hypotonia, transient episodes of hemiplegia, mental retardation, developmental delay, brain atrophy, headache, early morning nausea, vomiting, progressive sensorineural hearing loss and seizures (<xref ref-type="bibr" rid="B94">94</xref>). </p>
<p>
<bold>Blau syndrome</bold>
</p>
<p>This rare autosomal dominant syndrome clinically resembles early onset sarcoidosis characterized by granulomatous inflammation mostly involving joints, eyes and skin (<xref ref-type="bibr" rid="B95">95</xref>-<xref ref-type="bibr" rid="B97">97</xref>) and is caused by mutation in pattern recognition receptor NOD2 gene encoding a protein known as an intracellular sensor for bacterial products (<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>). This protein is activated after receiving signals from bacterial components resulting in activation of NFkB pathway which regulates innate responses (<xref ref-type="bibr" rid="B99">99</xref>). Neurological manifestations are rare and include cranial neuropathies (hearing loss) and transient 6<sup>th</sup> nerve palsy, cerebral vasculitis and cerebral infarction (<xref ref-type="bibr" rid="B100">100</xref>, <xref ref-type="bibr" rid="B101">101</xref>).</p>
<p>Aicardi-Goutieres syndrome</p>
<p>This is a genetically determined encephalopathy caused by mutations in TREX1 genes encoding RNAs involved in removing RNA, leading to the accumulation of endogenous RNA, triggering Toll-like receptor-dependent interferon-α production in the brain with the resultant activation of neurotoxic lymphocytes and immune system in addition to the inhibition of angiogenesis (<xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B103">103</xref>). Neurological manifestations include early infantile onset of irritability, spasticity, dystonic posturing, psychomotor retardation and microcephaly, resulting in death in early childhood (<xref ref-type="bibr" rid="B104">104</xref>).</p>
<p>
<bold>In conclusion, </bold>neurological manifestations of primary immunodeficiencies are common with diverse pathologic mechanisms. Neurological deficits may be mild or they may greatly influence the course of the disease with major impacts on the quality of life of the patients. Some of these complications may even cause death. Neurological manifestations may have an early onset, beginning at birth or they may appear later which in both situations may lead to misdiagnosis and delayed therapy. Therefore a high suspicion of an underlying primary immunodeficiency is important in any type of neurological problems occurring with recurrent infections.</p>
</sec>
<sec>
<title>Authors’ Contribution</title>
<p> All three authors were involved in data collection, and writing the article.</p>
</sec>
<sec>
<title>Conflict of Interest</title>
<p>The authors declare that there is no Conflict of Interest.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Al-Herz</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bousfiha</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Casanova</surname>
<given-names>J-L</given-names>
</name>
<name>
<surname>Chatila</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee report on inborn errors of immunity</article-title>
<source/> J Clin Immunol
          <year>2018</year>
<volume>38</volume>
<issue>1</issue>
<fpage>96</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="pmid">29226302</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samarghitean</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ortutay</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vihinen</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Systematic classification of primary immunodeficiencies based on clinical, pathological, and laboratory parameters</article-title>
<source/> J Immunol
          <year>2009</year>
<volume>183</volume>
<issue>11</issue>
<fpage>7569</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">19917694</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bousfiha</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jeddane</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ailal</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Al-Herz</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies</article-title>
<source/> J Clin Immunol
          <year>2018</year>
<volume>38</volume>
<issue>1</issue>
<fpage>129</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">29226301</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aydin</surname>
<given-names>ÖF</given-names>
</name>
<name>
<surname>Anlar</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Neurological Manifestations of Primary Immunodeficiency Diseases</article-title>
<source/> Clin Pediatr
          <year>2017</year>
<fpage>0009922817737083</fpage>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>MB</surname>
<given-names>HK L</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>NF</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>BS</surname>
<given-names>B</given-names>
</name>
<name>
<surname>W</surname>
<given-names>B</given-names>
</name>
<name>
<surname>WW</surname>
<given-names>B</given-names>
</name>
<name>
<surname>ST</surname>
<given-names>H</given-names>
</name>
<name>
<surname>RF</surname>
<given-names>LJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Approach to the patient with recurrent infections</article-title>
<source/>Middleton's Allergy Principles &amp;Practice. 2
          <year>2014</year>
<edition>8th ed</edition>
<publisher-loc>Philadelphia</publisher-loc>
<publisher-name>Elsevier Saunders</publisher-name>
<fpage>1140</fpage>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitmore</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>HB</given-names>
</name>
</person-group>
<article-title>Adenosine deaminase deficiency–more than just an immunodeficiency</article-title>
<source/> Front Immunol
          <year>2016</year>
<volume>7</volume>
<fpage>314</fpage>
<pub-id pub-id-type="pmid">27579027</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaspar</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Aiuti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Porta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Candotti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hershfield</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Notarangelo</surname>
<given-names>LD</given-names>
</name>
</person-group>
<article-title>How I treat ADA deficiency</article-title>
<source/> Blood
          <year>2009</year>
<volume>114</volume>
<issue>17</issue>
<fpage>3524</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">19638621</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dehkordy</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Aghamohammadi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ochs</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Rezaei</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Primary immunodeficiency diseases associated with neurologic manifestations</article-title>
<source/> J Clin Immunol
          <year>2012</year>
<volume>32</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">22038677</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nofech-Mozes</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Roifman</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Neurological manifestations in severe combined immunodeficiency secondary to adenosine deaminase deficiency: Three case reports and review of the literature</article-title>
<source/> J Allergy Clin Immunol
          <year>2005</year>
<volume>115</volume>
<issue>2</issue>
<fpage>S78</fpage>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chistiakov</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Voronova</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Chistiakov</surname>
<given-names>AP</given-names>
</name>
</person-group>
<article-title>Ligase IV syndrome</article-title>
<source/> Eur Journal Med Genet
          <year>2009</year>
<season>Nov-Dec</season>
<volume>52</volume>
<issue>6</issue>
<fpage>373</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">19467349</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>IJspeert</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Warris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Flier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reisli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Keles</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chishimba</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical spectrum of LIG4 deficiency is broadened with severe dysmaturity, primordial dwarfism, and neurological abnormalities</article-title>
<source/> Hum Mutat
          <year>2013</year>
<volume>34</volume>
<issue>12</issue>
<fpage>1611</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">24027040</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enders</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fisch</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Duffner</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Pannicke</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Nikolopoulos</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A severe form of human combined immunodeficiency due to mutations in DNA ligase IV</article-title>
<source/> J Immunol
          <year>2006</year>
<volume>176</volume>
<issue>8</issue>
<fpage>5060</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">16585603</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothblum-Oviatt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lefton-Greif</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>McGrath-Morrow</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>TO</given-names>
</name>
<name>
<surname>Lederman</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>Ataxia telangiectasia: a review</article-title>
<source/> Orphanet J Rare Dis
          <year>2016</year>
<month>11</month>
<volume>11</volume>
<issue>1</issue>
<lpage>159</lpage>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frappart</surname>
<given-names>P-O</given-names>
</name>
<name>
<surname>McKinnon</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Ataxia-telangiectasia and related diseases</article-title>
<source/> Neuromolecular Med
          <year>2006</year>
<volume>8</volume>
<issue>4</issue>
<fpage>495</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="pmid">17028372</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nowak-Wegrzyn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>TO</given-names>
</name>
<name>
<surname>Winkelstein</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Lederman</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>Immunodeficiency and infections in ataxia-telangiectasia</article-title>
<source/> J Pediatr
          <year>2004</year>
<volume>144</volume>
<issue>4</issue>
<fpage>505</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">15069401</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lockman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Iskander</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Bembea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>TO</given-names>
</name>
<name>
<surname>Lederman</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>McGrath-Morrow</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The critically ill patient with ataxia–telangiectasia: A case series</article-title>
<source/> Pediatr Crit Care Med
          <year>2012</year>
<volume>13</volume>
<issue>2</issue>
<fpage>e84</fpage>
<lpage>e90</lpage>
<pub-id pub-id-type="pmid">21478798</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schroeder</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Zielen</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Infections of the respiratory system in patients with ataxia-telangiectasia</article-title>
<source/> Pediatr Pulmonol
          <year>2014</year>
<month>4</month>
<volume>49</volume>
<issue>4</issue>
<fpage>389</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">23761391</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Skolasky</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rosquist</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lederman</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Survival probability in ataxia telangiectasia</article-title>
<source/> Arch Dis Child
          <year>2006</year>
<volume>91</volume>
<issue>7</issue>
<fpage>610</fpage>
<lpage>1</lpage>
<pub-id pub-id-type="pmid">16790721</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kraus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Levran</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nissenkorn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Levi</surname>
<given-names>YB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disturbed B and T cell homeostasis and neogenesis in patients with ataxia telangiectasia</article-title>
<source/> J Clin Immunol
          <year>2014</year>
<month>7</month>
<volume>34</volume>
<issue>5</issue>
<fpage>561</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">24789685</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Becker-Catania</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gatti</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Ataxia-telangiectasia: diagnosis and treatment</article-title>
<source/> Semin Pediatr Neurol
          <year>2003</year>
<month>9</month>
<volume>10</volume>
<issue>3</issue>
<fpage>173</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">14653405</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chrzanowska</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Gregorek</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dembowska-Baginska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kalina</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Digweed</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Nijmegen breakage syndrome (NBS)</article-title>
<source/> Orphanet J Rare Dis
          <year>2012</year>
<volume>7</volume>
<fpage>13</fpage>
<pub-id pub-id-type="pmid">22373003</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Distel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Neubauer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Varon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Holter</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Grabenbauer</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Fatal toxicity following radio‐and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen Breakage Syndrome</article-title>
<source/> Pediatr Blood Cancer
          <year>2003</year>
<volume>41</volume>
<issue>1</issue>
<fpage>44</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Wegner</surname>
<given-names>R-D</given-names>
</name>
<name>
<surname>German</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Chrzanowska</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Digweed</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stumm</surname>
<given-names>M</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Ochs</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CIE</given-names>
</name>
<name>
<surname>Puck</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Chromosomal instability syndromes other than ataxia-telangiectasia</article-title>
<source/>Primary immunodeficiency diseases A molecular and genetic approach
          <year>2007</year>
<fpage>2</fpage>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bekiesinska-Figatowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chrzanowska</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Jurkiewicz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wakulinska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rysiewskis</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gladkowska-Dura</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Magnetic resonance imaging of brain abnormalities in patients with the Nijmegen breakage syndrome</article-title>
<source/> Acta Neurobiol Exp
          <year>2004</year>
<volume>64</volume>
<issue>4</issue>
<fpage>503</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehrlich</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Weemaes</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Immunodeficiency, centromeric region instability, facial anomalies syndrome (ICF)</article-title>
<source/> Orphanet J Rare Dis
          <year>2006</year>
<volume>1</volume>
<issue>1</issue>
<fpage>2</fpage>
<pub-id pub-id-type="pmid">16722602</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Soo</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function</article-title>
<source/> Hum Mol Genet
          <year>2007</year>
<volume>17</volume>
<issue>5</issue>
<fpage>690</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="pmid">18029387</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagleitner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lankester</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maraschio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hulten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fryns</surname>
<given-names>J-P</given-names>
</name>
<name>
<surname>Schuetz</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome)</article-title>
<source/> J Medical Genet
          <year>2008</year>
<volume>45</volume>
<issue>2</issue>
<fpage>93</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blundred</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>DNA double-strand break repair, immunodeficiency and the RIDDLE syndrome</article-title>
<source/> Expert Rev Clin Immunol
          <year>2011</year>
<volume>7</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">21426255</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>DA</surname>
<given-names>D</given-names>
</name>
<name>
<surname>KE</surname>
<given-names>S</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Ochs</surname>
<given-names>HD SC</given-names>
</name>
<name>
<surname>Puck</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>DiGeorge Syndrome: a chromosome 22q11.2 deletion syndrome</article-title>
<source/>Primary Immunodeficiency Diseases A Molecular and Genetic Approach. 3rd ed. New York
          <year>2014</year>
<publisher-name>Oxford University Press</publisher-name>
<fpage>580</fpage>
<lpage>92</lpage>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gothelf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schaer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Eliez</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Genes, brain development and psychiatric phenotypes in velo‐cardio‐facial syndrome</article-title>
<source/> Dev Disabil Res Rev
          <year>2008</year>
<volume>14</volume>
<issue>1</issue>
<fpage>59</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">18636637</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>E-H</given-names>
</name>
<name>
<surname>Yum</surname>
<given-names>M-S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B-H</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H-W</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H-J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>G-H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy and other neuropsychiatric manifestations in children and adolescents with 22q11 2 deletion syndrome</article-title>
<source/> J Clin Neurol
          <year>2016</year>
<volume>12</volume>
<issue>1</issue>
<fpage>85</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">26754781</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Eliez</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>From genes to brain: understanding brain development in neurogenetic disorders using neuroimaging techniques</article-title>
<source/> Child Adolesc Psychiatr Clin N Am
          <year>2007</year>
<volume>16</volume>
<issue>3</issue>
<fpage>557</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="pmid">17562579</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinoshita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kokudo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ide</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Homma</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A patient with DiGeorge syndrome with spina bifida and sacral myelomeningocele, who developed both hypocalcemia-induced seizure and epilepsy</article-title>
<source/> Seizure-Eur J Epilep
          <year>2010</year>
<volume>19</volume>
<issue>5</issue>
<fpage>303</fpage>
<lpage>5</lpage>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fliegauf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grimbacher</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Hyper-IgE syndromes: reviewing PGM3 deficiency</article-title>
<source/> Curr Opin Pediatr
          <year>2014</year>
<volume>26</volume>
<issue>6</issue>
<fpage>697</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="pmid">25365149</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes</article-title>
<source/> Pediatr Res
          <year>2009</year>
<volume>65</volume>
<issue>5</issue>
<fpage>32R</fpage>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renner</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Puck</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frosch</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity</article-title>
<source/> J Pediatr
          <year>2004</year>
<volume>144</volume>
<issue>1</issue>
<fpage>93</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">14722525</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Clinical manifestations of hyper IgE syndromes</article-title>
<source/> Dis Markers
          <year>2010</year>
<volume>29</volume>
<issue>3, 4</issue>
<fpage>123</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">21178271</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yavuz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chee</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>A review on the vascular features of the hyperimmunoglobulin E syndrome</article-title>
<source/> Clin Exp Immunol
          <year>2010</year>
<volume>159</volume>
<issue>3</issue>
<fpage>238</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">19912258</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rael</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>McClain</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>The hyper-IgE syndromes: lessons in nature, from bench to bedside</article-title>
<source/> World Allergy Organ J
          <year>2012</year>
<volume>5</volume>
<issue>7</issue>
<fpage>79</fpage>
<pub-id pub-id-type="pmid">23283142</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghaffari</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ahanchian</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zandieh</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Update on Hyper IgE syndrome (HIES)</article-title>
<source/> J Pediatr Rev
          <year>2014</year>
<volume>2</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>46</lpage>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ichikawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lyons</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Datta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lamborn</surname>
<given-names>IT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment</article-title>
<source/> J Allergy Clin Immunol
          <year>2014</year>
<month>5</month>
<volume>133</volume>
<issue>5</issue>
<fpage>1400</fpage>
<comment>9, 9 e1-5</comment>
<pub-id pub-id-type="pmid">24589341</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kilic</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Donmez</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sloan</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Elizondo</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>André</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of migraine‐like headaches with Schimke immuno‐osseous dysplasia</article-title>
<source/> Am J Med Genet A
          <year>2005</year>
<volume>135</volume>
<issue>2</issue>
<fpage>206</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">15884045</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clewing</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Antalfy</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Lucke</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Najafian</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Marwedel</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Schimke immuno-osseous dysplasia: a clinicopathological correlation</article-title>
<source/> J Med Genet
          <year>2007</year>
<month>2</month>
<volume>44</volume>
<issue>2</issue>
<fpage>122</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">16840568</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Clewing</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Elizondo</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Hirano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurologic phenotype of Schimke immuno-osseous dysplasia and neurodevelopmental expression of SMARCAL1</article-title>
<source/> J Neuropathol Exp Neurol
          <year>2008</year>
<volume>67</volume>
<issue>6</issue>
<fpage>565</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">18520775</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vulliamy</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dokal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex</article-title>
<source/> Biochimie
          <year>2008</year>
<volume>90</volume>
<issue>1</issue>
<fpage>122</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">17825470</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glousker</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Touzot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Revy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tzfati</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Savage</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Unraveling the pathogenesis of Hoyeraal–Hreidarsson syndrome, a complex telomere biology disorder</article-title>
<source/> Br J Haematol
          <year>2015</year>
<volume>170</volume>
<issue>4</issue>
<fpage>457</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">25940403</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearson</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Al‐Eyadhy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Al‐Tamemi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mazer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dror</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An intronic mutation in DKC1 in an infant with Høyeraal–Hreidarsson syndrome</article-title>
<source/> Am J Med Genet A
          <year>2008</year>
<volume>146</volume>
<issue>16</issue>
<fpage>2159</fpage>
<lpage>61</lpage>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeates</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Slatter</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gennery</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Infusion of Sibling Marrow in a Patient with Purine Nucleoside Phosphorylase Deficiency Leads to Split Mixed Donor Chimerism and Normal Immunity</article-title>
<source/> Front Pediatr
          <year>2017</year>
<volume>5</volume>
<fpage>143</fpage>
<pub-id pub-id-type="pmid">28674683</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La</surname>
<given-names>Marca G</given-names>
</name>
<name>
<surname>Canessa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Giocaliere</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Malvagia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Funghini</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using tandem mass spectrometry on dried blood spots</article-title>
<source/> J Allergy Clin Immunol
          <year>2014</year>
<volume>134</volume>
<issue>1</issue>
<fpage>155</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">24767876</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozkinay</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pehlivan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Onay</surname>
<given-names>H</given-names>
</name>
<name>
<surname>van</surname>
<given-names>den Berg P</given-names>
</name>
<name>
<surname>Vardar</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Koturoglu</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Purine nucleoside phosphorylase deficiency in a patient with spastic paraplegia and recurrent infections</article-title>
<source/> J Child Neurol
          <year>2007</year>
<volume>22</volume>
<issue>6</issue>
<fpage>741</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">17641261</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>T</surname>
<given-names>R</given-names>
</name>
<name>
<surname>M</surname>
<given-names>W</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Ochs</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CIE</given-names>
</name>
<name>
<surname>Puck</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Hepatic veno-occlusive disease with immunodeficiency</article-title>
<source/>Primary Immunodeficiency DiseasesA molecular and genetic approach
          <edition>3rd ed</edition>
<publisher-loc>New York</publisher-loc>
<publisher-name>Oxford University Press</publisher-name>
<fpage>501</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cullup</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kho</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Dionisi-Vici</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brandmeier</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Urry</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy</article-title>
<source/> Nat Genet
          <year>2013</year>
<volume>45</volume>
<issue>1</issue>
<fpage>83</fpage>
<pub-id pub-id-type="pmid">23222957</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finocchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Angelino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cantarutti</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Corbari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bevivino</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cascioli</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immunodeficiency in Vici syndrome: a heterogeneous phenotype</article-title>
<source/> Am J Med Genet A
          <year>2012</year>
<volume>158</volume>
<issue>2</issue>
<fpage>434</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Peripheral neuropathy associated with common variable immunodeficiency</article-title>
<source/> Eur J Neurol
          <year>2000</year>
<volume>7</volume>
<issue>5</issue>
<fpage>573</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">11054146</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozdemir</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Okan</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Kilic</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Chronic inflammatory demyelinating polyneuropathy in common variable immunodeficiency</article-title>
<source/> Pediatr Neurol
          <year>2012</year>
<month>4</month>
<volume>46</volume>
<issue>4</issue>
<fpage>260</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="pmid">22490776</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>JT-U</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>DeRisi</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Gundling</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Neurologic complications of common variable immunodeficiency</article-title>
<source/> J Clin Immunol
          <year>2016</year>
<volume>36</volume>
<issue>8</issue>
<fpage>793</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="pmid">27704236</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nogueira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pita</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Constanço</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurological complications of common variable immunodeficiency: the immune system in chaos</article-title>
<source/> Int J Clin Neurosci Ment Health
          <year>2016</year>
<month>3</month>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aslam</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Misbah</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chapel</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Vitamin E deficiency induced neurological disease in common variable immunodeficiency: two cases and a review of the literature of vitamin E deficiency</article-title>
<source/> Clin Immunol
          <year>2004</year>
<volume>112</volume>
<issue>1</issue>
<fpage>24</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">15207778</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jolles</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The variable in common variable immunodeficiency: a disease of complex phenotypes</article-title>
<source/> J Allergy Clin Immunol Pract
          <year>2013</year>
<volume>1</volume>
<issue>6</issue>
<fpage>545</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">24565700</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>CIE</surname>
<given-names>S</given-names>
</name>
<name>
<surname>ME</surname>
<given-names>C</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Ochs</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CIE</given-names>
</name>
<name>
<surname>Puck</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>editor</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>X-linked agammaglobulinemia and autosomal recessive agammaglobulinemia</article-title>
<source/>Primary Immunodeficiency DiseasesA molecular and genetic approach
          <year>2014</year>
<edition>3rd ed</edition>
<publisher-loc>New York</publisher-loc>
<publisher-name>Oxford University Press</publisher-name>
<fpage>299</fpage>
<lpage>323</lpage>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quartier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Foray</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Casanova</surname>
<given-names>J-L</given-names>
</name>
<name>
<surname>Hau-Rainsard</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Blanche</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Enteroviral meningoencephalitis in X-linked agammaglobulinemia: intensive immunoglobulin therapy and sequential viral detection in cerebrospinal fluid by polymerase chain reaction</article-title>
<source/> Pediatr Infect Dis J
          <year>2000</year>
<volume>19</volume>
<issue>11</issue>
<fpage>1106</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">11099099</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sag</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Saka</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ozgur</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Sanal</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ayvaz</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Elibol</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Progressive neurodegenerative syndrome in a patient with X-linked agammaglobulinemia receiving intravenous immunoglobulin therapy</article-title>
<source/> Cogn Behav Neurol
          <year>2014</year>
<volume>27</volume>
<issue>3</issue>
<fpage>155</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">25237746</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>De</surname>
<given-names>Domenico I</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Chediak-Higashi syndrome</article-title>
<source/> Curr Opin Hematol
          <year>2008</year>
<month>1</month>
<volume>15</volume>
<issue>1</issue>
<fpage>22</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">18043242</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tardieu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lacroix</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Neven</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bordigoni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>de</surname>
<given-names>Saint Basile G</given-names>
</name>
<name>
<surname>Blanche</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome</article-title>
<source/> Blood
          <year>2005</year>
<volume>106</volume>
<issue>1</issue>
<fpage>40</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="pmid">15790783</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dotta</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Parolini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Prandini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tabellini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Antolini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kingsmore</surname>
<given-names>SF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism</article-title>
<source/> Orphanet J Rare Dis
          <year>2013</year>
<volume>8</volume>
<issue>1</issue>
<fpage>168</fpage>
<pub-id pub-id-type="pmid">24134793</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bohn</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Allroth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boztug</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brandes</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sandrock</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2</article-title>
<source/> Blood
          <year>2006</year>
<volume>108</volume>
<issue>1</issue>
<fpage>362</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">16537806</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wenham</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grieve</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cummins</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Booth</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kilner</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Two patients with Hermansky Pudlak syndrome type 2 and novel mutations in AP3B1</article-title>
<source/> Haematologica
          <year>2010</year>
<volume>95</volume>
<issue>2</issue>
<fpage>333</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">19679886</pub-id>
</element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ammann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krägeloh-Mann</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dieckmann</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Niethammer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome</article-title>
<source/> Blood
          <year>2016</year>
<volume>127</volume>
<issue>8</issue>
<fpage>997</fpage>
<lpage>1006</lpage>
<pub-id pub-id-type="pmid">26744459</pub-id>
</element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badolato</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Parolini</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Novel insights from adaptor protein 3 complex deficiency</article-title>
<source/> J Allergy Clin Immunol
          <year>2007</year>
<volume>120</volume>
<issue>4</issue>
<fpage>735</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">17931556</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Decaminada</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cappellini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mortilla</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Del</surname>
<given-names>Giudice E</given-names>
</name>
<name>
<surname>Sieni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Caselli</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Familial hemophagocytic lymphohistiocytosis: clinical and neuroradiological findings and review of the literature</article-title>
<source/> Childs Nerv Syst
          <year>2010</year>
<month>1</month>
<volume>26</volume>
<issue>1</issue>
<fpage>121</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">19649640</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weitzman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy</article-title>
<source/> Expert Rev Clin Immunol
          <year>2010</year>
<volume>6</volume>
<issue>1</issue>
<fpage>137</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">20383897</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Woodbine</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Björkman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fawcett</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>XRCC4 deficiency in human subjects causes a marked neurological phenotype but no overt immunodeficiency</article-title>
<source/> J Allergy Clin Immunol
          <year>2015</year>
<volume>136</volume>
<issue>4</issue>
<fpage>1007</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">26255102</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>M-M</given-names>
</name>
<name>
<surname>Yum</surname>
<given-names>M-S</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H-W</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>T-S</given-names>
</name>
<name>
<surname>Im</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>J-J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Central nervous system (CNS) involvement is a critical prognostic factor for hemophagocytic lymphohistiocytosis</article-title>
<source/> Korean J Hematol
          <year>2012</year>
<volume>47</volume>
<issue>4</issue>
<fpage>273</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">23320006</pub-id>
</element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janka</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Familial and acquired hemophagocytic lymphohistiocytosis</article-title>
<source/> Eur J Pediatr
          <year>2007</year>
<month>2</month>
<volume>166</volume>
<issue>2</issue>
<fpage>95</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">17151879</pub-id>
</element-citation>
</ref>
<ref id="B75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jaishankar</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Saleh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jithpratuck</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sahni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Krishnaswamy</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Chronic granulomatous disease: a review of the infectious and inflammatory complications</article-title>
<source/> Clin Mol Allergy
          <year>2011</year>
<volume>9</volume>
<issue>1</issue>
<fpage>10</fpage>
<pub-id pub-id-type="pmid">21624140</pub-id>
</element-citation>
</ref>
<ref id="B76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finocchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Claps</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Serafinelli</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Salfa</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>Matteo G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic granulomatous disease presenting with salmonella brain abscesses</article-title>
<source/> Pediatr Infect Disease J
          <year>2014</year>
<volume>33</volume>
<issue>5</issue>
<fpage>525</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">24445825</pub-id>
</element-citation>
</ref>
<ref id="B77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlsson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Van’t</surname>
<given-names>Hooft I</given-names>
</name>
<name>
<surname>Melin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Entesarian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Laurencikas</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nennesmo</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Central nervous system involvement in severe congenital neutropenia: neurological and neuropsychological abnormalities associated with specific HAX1 mutations</article-title>
<source/> J Intern Med
          <year>2008</year>
<volume>264</volume>
<issue>4</issue>
<fpage>388</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="pmid">18513342</pub-id>
</element-citation>
</ref>
<ref id="B78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Germeshausen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grudzien</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zeidler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Abdollahpour</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yetgin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rezaei</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations</article-title>
<source/> Blood
          <year>2008</year>
<volume>111</volume>
<issue>10</issue>
<fpage>4954</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">18337561</pub-id>
</element-citation>
</ref>
<ref id="B79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rezaei</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chavoshzadeh</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Alaei</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sandrock</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Association of HAX1 deficiency with neurological disorder</article-title>
<source/> Neuropediatrics
          <year>2007</year>
<volume>38</volume>
<issue>05</issue>
<fpage>261</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">18330843</pub-id>
</element-citation>
</ref>
<ref id="B80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boocock</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Popovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Durie</surname>
<given-names>PR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in SBDS are associated with Shwachman–Diamond syndrome</article-title>
<source/> Nat Genet
          <year>2003</year>
<volume>33</volume>
<issue>1</issue>
<fpage>97</fpage>
<pub-id pub-id-type="pmid">12496757</pub-id>
</element-citation>
</ref>
<ref id="B81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerr</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dupuis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rommens</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Durie</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>The behavioral phenotype of school-age children with shwachman diamond syndrome indicates neurocognitive dysfunction with loss of Shwachman-Bodian-Diamond syndrome gene function</article-title>
<source/> J Pediatr
          <year>2010</year>
<volume>156</volume>
<issue>3</issue>
<fpage>433</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">19906387</pub-id>
</element-citation>
</ref>
<ref id="B82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toiviainen‐Salo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mäkitie</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Mannerkoski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hämäläinen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Valanne</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Autti</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Shwachman–Diamond syndrome is associated with structural brain alterations on MRI</article-title>
<source/> Am J Med Gene A
          <year>2008</year>
<volume>146</volume>
<issue>12</issue>
<fpage>1558</fpage>
<lpage>64</lpage>
</element-citation>
</ref>
<ref id="B83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gazit</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mory</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Etzioni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Frydman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scheuerman</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Gershoni-Baruch</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Leukocyte adhesion deficiency type II: long-term follow-up and review of the literature</article-title>
<source/> J Clin Immunol
          <year>2010</year>
<month>3</month>
<volume>30</volume>
<issue>2</issue>
<fpage>308</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">20099014</pub-id>
</element-citation>
</ref>
<ref id="B84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yakubenia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Leukocyte adhesion deficiency II</article-title>
<source/> The FEBS J
          <year>2006</year>
<volume>273</volume>
<issue>19</issue>
<fpage>4390</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">16956371</pub-id>
</element-citation>
</ref>
<ref id="B85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Etzioni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tonetti</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Leukocyte adhesion deficiency II–from A to almost Z</article-title>
<source/> Immunol Rev
          <year>2000</year>
<volume>178</volume>
<issue>1</issue>
<fpage>138</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">11213799</pub-id>
</element-citation>
</ref>
<ref id="B86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moulding</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Record</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Malinova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thrasher</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Actin cytoskeletal defects in immunodeficiency</article-title>
<source/> Immunol Rev
          <year>2013</year>
<volume>256</volume>
<issue>1</issue>
<fpage>282</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">24117828</pub-id>
</element-citation>
</ref>
<ref id="B87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kremer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wevers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Scheffer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>De</surname>
<given-names>Jong J</given-names>
</name>
<name>
<surname>Van</surname>
<given-names>der Meer J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mevalonate kinase deficiency Evidence for a phenotypic continuum</article-title>
<source/> Neurology
          <year>2004</year>
<volume>62</volume>
<issue>6</issue>
<fpage>994</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">15037710</pub-id>
</element-citation>
</ref>
<ref id="B88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van</surname>
<given-names>der Burgh R</given-names>
</name>
<name>
<surname>ter</surname>
<given-names>Haar NM</given-names>
</name>
<name>
<surname>Boes</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Frenkel</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Mevalonate kinase deficiency, a metabolic autoinflammatory disease</article-title>
<source/> Clin Immunol
          <year>2013</year>
<volume>147</volume>
<issue>3</issue>
<fpage>197</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">23110805</pub-id>
</element-citation>
</ref>
<ref id="B89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Natural history of mevalonate kinase deficiency: a literature review</article-title>
<source/> Pediatr Rheumatol
          <year>2016</year>
<volume>14</volume>
<issue>1</issue>
<fpage>30</fpage>
</element-citation>
</ref>
<ref id="B90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldmann</surname>
<given-names>Jm</given-names>
</name>
<name>
<surname>Prieur</surname>
<given-names>A-M</given-names>
</name>
<name>
<surname>Quartier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Berquin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Certain</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cortis</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes</article-title>
<source/> Am J Hum Genet
          <year>2002</year>
<volume>71</volume>
<issue>1</issue>
<fpage>198</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="pmid">12032915</pub-id>
</element-citation>
</ref>
<ref id="B91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutterwala</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Ogura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Szczepanik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lara-Tejero</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lichtenberger</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>EP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1</article-title>
<source/> Immunity
          <year>2006</year>
<volume>24</volume>
<issue>3</issue>
<fpage>317</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">16546100</pub-id>
</element-citation>
</ref>
<ref id="B92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubota</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Koike</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Cryopyrin-associated periodic syndromes: background and therapeutics</article-title>
<source/> Mod Rheumatol
          <year>2010</year>
<volume>20</volume>
<issue>3</issue>
<fpage>213</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">20140476</pub-id>
</element-citation>
</ref>
<ref id="B93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffman</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Wanderer</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>Inflammasome and IL-1β-mediated disorders</article-title>
<source/> Curr Allergy Asthma Rep
          <year>2010</year>
<volume>10</volume>
<issue>4</issue>
<fpage>229</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">20425006</pub-id>
</element-citation>
</ref>
<ref id="B94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Omenetti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Federici</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Caorsi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gattorno</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Chronic infantile neurological cutaneous and articular (CINCA) syndrome: a review</article-title>
<source/> Orphanet J Rare Dis
          <year>2016</year>
<volume>11</volume>
<issue>1</issue>
<fpage>167</fpage>
<pub-id pub-id-type="pmid">27927236</pub-id>
</element-citation>
</ref>
<ref id="B95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Punzi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Furlan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Podswiadek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gava</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Valente</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De</surname>
<given-names>Marchi M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review</article-title>
<source/> Autoimmun Rev
          <year>2009</year>
<volume>8</volume>
<issue>3</issue>
<fpage>228</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">18718560</pub-id>
</element-citation>
</ref>
<ref id="B96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosé</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>McIlvain-Simpson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Coffman</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Rosenbaum</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Davey</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis</article-title>
<source/> J Rheumatol
          <year>2005</year>
<volume>32</volume>
<issue>2</issue>
<fpage>373</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">15693102</pub-id>
</element-citation>
</ref>
<ref id="B97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanazawa</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation</article-title>
<source/> J Invest Dermatol
          <year>2004</year>
<volume>122</volume>
<fpage>851</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="pmid">15086578</pub-id>
</element-citation>
</ref>
<ref id="B98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kurz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The NOD2 defect in Blau syndrome does not result in excess interleukin‐1 activity</article-title>
<source/> Arthritis Rheum
          <year>2009</year>
<volume>60</volume>
<issue>2</issue>
<fpage>611</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">19180500</pub-id>
</element-citation>
</ref>
<ref id="B99">
<label>99</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Brydges</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kastner</surname>
<given-names>D</given-names>
</name>
</person-group>
<source/>The systemic autoinflammatory diseases: inborn errors of the innate immune system Current Concepts in Autoimmunity and Chronic Inflammation
          <year>2006</year>
<publisher-name>Springer</publisher-name>
<fpage>127</fpage>
<lpage>60</lpage>
</element-citation>
</ref>
<ref id="B100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caso</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Galozzi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sfriso</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cantarini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Punzi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease</article-title>
<source/> RMD Open
          <year>2015</year>
<volume>1</volume>
<issue>1</issue>
<fpage>e000097</fpage>
<pub-id pub-id-type="pmid">26509073</pub-id>
</element-citation>
</ref>
<ref id="B101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosé</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Pans</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Casteels</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Anton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bader-Meunier</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brissaud</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes</article-title>
<source/> Rheumatology
          <year>2014</year>
<volume>54</volume>
<issue>6</issue>
<fpage>1008</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">25416713</pub-id>
</element-citation>
</ref>
<ref id="B102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pulliero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fazzi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cartiglia</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Orcesi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Balottin</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Uggetti</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Aicardi–Goutieres syndrome Molecular and clinical features of RNAse deficiency and microRNA overload</article-title>
<source/> Mutat Res
          <year>2011</year>
<volume>717</volume>
<issue>1</issue>
<fpage>99</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">21524657</pub-id>
</element-citation>
</ref>
<ref id="B103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crow</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Rehwinkel</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity</article-title>
<source/> Hum Mol Genet
          <year>2009</year>
<volume>18</volume>
<issue>R2</issue>
<fpage>R130</fpage>
<lpage>R6</lpage>
<pub-id pub-id-type="pmid">19808788</pub-id>
</element-citation>
</ref>
<ref id="B104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crow</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Hayward</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Parmar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Robins</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Leitch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus</article-title>
<source/> Nat Genet
          <year>2006</year>
<volume>38</volume>
<issue>8</issue>
<fpage>917</fpage>
<pub-id pub-id-type="pmid">16845398</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>